Endophthalmitis following same-day bilateral anti-VEGF injections: a systematic review.
Adverse event
Anti-VEGF
Bilateral
Endophthalmitis
Injection
Intravitreal
Risk
Same-day
Same-session
Systematic review
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
08 Feb 2024
08 Feb 2024
Historique:
received:
04
09
2023
accepted:
29
10
2023
medline:
9
2
2024
pubmed:
9
2
2024
entrez:
9
2
2024
Statut:
epublish
Résumé
To review the risk of endophthalmitis in same-day bilateral anti-VEGF injections. We searched 12 literature databases for studies on the risk of endophthalmitis after same-day bilateral intravitreal anti-VEGF injections. Data extraction was made independently by two authors and discussed afterward until reaching consensus. Seventeen studies were included with a total of 138,478 intravitreal anti-VEGF injections (69,239 bilateral injections sessions) given in at least 7579 patients. In total, 33 cases of endophthalmitis had occurred, and no cases were bilateral. The incidence of endophthalmitis ranged from 0 to 0.53% per intravitreal injection across studies. We suggest that clinicians can consider same-day treatment of both eyes of patients in need of bilateral intravitreal anti-VEGF injection therapy, but larger studies are needed to quantify the exact risk of endophthalmitis.
Identifiants
pubmed: 38332399
doi: 10.1007/s10792-024-02983-4
pii: 10.1007/s10792-024-02983-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
37Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Bloch SB, Larsen M (2015) Translational public health care perspective: Intravitreal treatment of neovascular age-related macular degeneration has revolutionized clinical ophthalmology. Acta Ophthalmol
Lee AY, Day AC, Egan C, Bailey C, Johnston RL, Tsaloumas MD et al. (2016) Previous intravitreal therapy is associated with increased risk of posterior capsule rupture during cataract surgery. Ophthalmology
Williams GA (2014). IVT injections: health policy implications. Rev Ophthalmol
Meer EA, Oh DH, Brodie FL (2022) Time and distance cost of longer acting anti-VEGF therapies for macular degeneration: contributions to drug cost comparisons. Clin Ophthalmol 16:4273–4279
doi: 10.2147/OPTH.S384995
pubmed: 36578665
pmcid: 9792116
Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R (2015) Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol 160(4):725–31.e1
doi: 10.1016/j.ajo.2015.06.023
pubmed: 26142721
Mahajan VB, Elkins KA, Russell SR, Boldt HC, Gehrs KM, Weingeist TA et al (2011) Bilateral intravitreal injection of antivascular endothelial growth factor therapy. Retina 31(1):31–35
doi: 10.1097/IAE.0b013e3181ed8c80
pubmed: 21187731
Merani R, Hunyor AP (2015) Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. Int J Retin Vitr 1:9
doi: 10.1186/s40942-015-0010-y
Borkar DS, Obeid A, Su DC, Storey PP, Gao X, Regillo CD et al (2018) Endophthalmitis rates after bilateral same-day intravitreal anti-vascular endothelial growth factor injections. Am J Ophthalmol 194:1–6
doi: 10.1016/j.ajo.2018.06.022
pubmed: 29981738
Tabatabaii A, Ahmadraji A, Khodabande A, Mansouri M (2013) Acute bilateral endophthalmitis following bilateral intravitreal bevacizumab (avastin) injection. Middle East Afr J Ophthalmol 20(1):87–88
doi: 10.4103/0974-9233.106402
pubmed: 23580860
pmcid: 3617537
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VAE (2019) Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane,. https://www.training.cochrane.org/handbook . Accessed July 18, 2022
Okoye O, Okonkwo O, Oderinlo O, Hassan K, Ijasan A (2016) Bilateral concomitant intravitreal anti-vascular endothelial growth factor injection: Experience in a Nigerian tertiary private eye care facility. Niger J Clin Pract 19(4):544–548
doi: 10.4103/1119-3077.183313
pubmed: 27251975
Ruão M, Andreu-Fenoll M, Dolz-Marco R, Gallego-Pinazo R (2017) Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents. Clin Ophthalmol 11:299–302
doi: 10.2147/OPTH.S124282
pubmed: 28203056
pmcid: 5295803
Bagheri S, Koulouri I, Konstantinou E, Erenler F, Vavvas DG (2018) Visual outcome of bilateral same-session intravitreal anti-VEGF injections. Invest Ophthalmol Vis Sci 59(9):835
Juncal VR, Francisconi CLM, Altomare F, Chow DR, Giavedoni LR, Muni RH et al (2019) Same-day bilateral intravitreal anti-vascular endothelial growth factor injections: experience of a large canadian retina center. Ophthalmol J Int d’ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkd 242(1):1–7
doi: 10.1159/000499115
Ali FS, Jenkins TL, Boparai RS, Obeid A, Ryan ME, Wibblesman TD et al (2021) Aqueous chlorhexidine compared with povidone-iodine as ocular antisepsis before intravitreal injection: a randomized clinical trial. Ophthalmol Retin 5(8):788–796
doi: 10.1016/j.oret.2020.11.008
Jang K, Ahn J, Sohn J, Hwang DDJ (2020) Evaluation of the safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents: experience of a large korean retina center. Clin Ophthalmol 14:3211–3218
doi: 10.2147/OPTH.S276620
pubmed: 33116371
pmcid: 7567572
Jeeva IK, Masud S, Siddiqui MAR, Fahad HM (2022) Safety of simultaneous bilateral intravitreal versus unilateral anti-vasculo-endothelial growth factors injection in an operating room setting. Pakistan J Med Sci 38(8):2324–2330
Lima LH, Zweifel SA, Engelbert M, Sorenson JA, Slakter JS, Cooney MJ et al (2009) Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina 29(9):1213–1217
doi: 10.1097/IAE.0b013e3181b32d27
pubmed: 19934815
Davis RP, Schefler AC, Murray TG (2010) Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration. Clin Ophthalmol 4:703–707
pubmed: 20689785
pmcid: 2915855
Cimbalas A, Svalbonaite E LG and AR (2012) Simultaneous and separate time bilateral intravitreal injection for patients with neovascular AMD and poor baseline visual acuity. Acta Ophthalmol, 250
Gregori NZ, Weiss MJ, Goldhardt R, Schiffman JC, Vega E, Mattis CA, et al. (2012) Randomized clinical trial of two anesthetic techniques for intravitreal injections: 4% liquid lidocaine on cotton swabs versus 3.5% lidocaine gel. Expert Opin Drug Deliv. 9(7):735–741
Shah M, Amoaku WMK. Same-day consecutive bilateral intravitreal injections of ranibizumab for the treatment of bilateral active choroidal neovascularization in age-related macular degeneration, vol 90. Acta Ophthalmol. England, p e491–e493
Abu-Yaghi NE, Shokry AN, Abu-Sbeit RH (2014) Bilateral same-session intravitreal injections of anti-vascular endothelial growth factors. Int J Ophthalmol 7(6):1017–1021
pubmed: 25540758
pmcid: 4270969
Chao DL, Gregori NZ, Khandji J, Goldhardt R (2014) Safety of bilateral intravitreal injections delivered in a teaching institution, vol 11, Expert opinion on drug delivery. England. pp 991–993.
Giocanti-Auregan A, Tadayoni R, Grenet T, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C et al (2016) Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. BMC Ophthalmol 16:142
doi: 10.1186/s12886-016-0317-y
pubmed: 27507298
pmcid: 4979182
Fileta JB, Scott IU, Flynn HWJ (2014) Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina 45(2):143–149
doi: 10.3928/23258160-20140306-08
pubmed: 24635156
McCannel CA (2011) Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 31(4):654–661
doi: 10.1097/IAE.0b013e31820a67e4
pubmed: 21330939
Sachdeva MM, Moshiri A, Leder HA, Scott AW (2016) Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms. J Ophthalmic Inflamm Infect 6(1):2
doi: 10.1186/s12348-015-0069-5
pubmed: 26758203
pmcid: 4710619
Green-Simms AE, Ekdawi NS, Bakri SJ (2011) Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol 151(2):329–332
doi: 10.1016/j.ajo.2010.08.039
pubmed: 21168821
Chaturvedi R, Wannamaker KW, Riviere PJ, Khanani AM, Wykoff CC, Chao DL (2019) Real-world trends in intravitreal injection practices among american retina specialists. Ophthalmol Retin 3(8):656–662
doi: 10.1016/j.oret.2019.03.023
Lau PE, Jenkins KS, Layton CJ (2018) Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections. J Ophthalmol 2018:8567912
doi: 10.1155/2018/8567912
pubmed: 30174946
pmcid: 6098904
Falavarjani KG, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 27(7):787–794
doi: 10.1038/eye.2013.107
pubmed: 23722722
Freund KB, Vance SK (2011) Systemic safety of bilateral intravitreal anti-vascular endothelial growth factor injections, vol 31, Retina (Philadelphia, Pa.). United States, pp 1–3